Literature DB >> 18657947

Increased nitric oxide release by neutrophils of a patient with tyrosinemia type III.

Patrizia D'Eufemia1, Roberto Finocchiaro, Mauro Celli, Ivana Raccio, Enrico Properzi, Alessandra Zicari.   

Abstract

Tyrosinemia type III (OMIM 276710) is an autosomal recessive disorder caused by the deficiency of 4-hydroxyphenylpyruvate dioxygenase (4-HPD). Few cases have been described with mental retardation or neurological symptoms. Recently it has been demonstrated that 4-HPD participates to nitric oxide (NO) intracellular sequestration in Pseudomonas aeruginosa. 4-HPD is an ubiquitous enzyme with a prominent expression in neutrophils and neurons. In the nervous system NO has been perceived to be a potential neuromodulator although prolonged excessive generation is detrimental. We analyzed NO release by neutrophils of a patient with tyrosinemia type III in order to evaluate a possible influence of 4-HPD deficiency on this process. Our patient, previously described, is a 30-year-old women with persistent tyrosinemia (450-680 micromol/l) and deficient activity of 4-HPD. At 17 months of age she experienced an acute ataxia and drowsiness lasting for 10 days, but further clinical course showed persistent tyrosinemia with normal growth and psychomotor development. Neutrophils isolated from our patient exhibited a NO release greatly higher in respect to the controls (mean+/-SEM 23.2+/-1.8 micromol/10(6) cells vs 3.5+/-0.5 micromol/10(6) cells). Clinical findings of tyrosinemia type III include neurological symptoms and mental retardation but no consistent phenotype has emerged. Therefore the pathogenesis of neurological involvement is yet not well understood. Our results suggest that an excessive neutrophils of NO release could reflect the lack of scavenging action of 4-HPD. Considering the prominent expression of this enzyme in neurons, we hypothesize that excessive NO release could participate in neuronal damage explaining the neurological involvement described in patients with tyrosinemia type III.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657947     DOI: 10.1016/j.biopha.2008.06.030

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Effect of L-tyrosine in vitro and in vivo on energy metabolism parameters in brain and liver of young rats.

Authors:  Gabriela K Ferreira; Giselli Scaini; Milena Carvalho-Silva; Lara M Gomes; Lislaine S Borges; Júlia S Vieira; Larissa S Constantino; Gustavo C Ferreira; Patrícia F Schuck; Emilio L Streck
Journal:  Neurotox Res       Date:  2012-07-31       Impact factor: 3.911

2.  Tyrosinemia type III in an asymptomatic girl.

Authors:  Edyta Szymanska; Malgorzata Sredzinska; Elzbieta Ciara; Dorota Piekutowska-Abramczuk; Rafal Ploski; Dariusz Rokicki; Anna Tylki-Szymanska
Journal:  Mol Genet Metab Rep       Date:  2015-10-22

Review 3.  TYROSINEMIA TYPE III: A CASE REPORT OF SIBLINGS AND LITERATURE REVIEW.

Authors:  Fábio Barroso; Joana Correia; Anabela Bandeira; Carla Carmona; Laura Vilarinho; Manuela Almeida; Júlio César Rocha; Esmeralda Martins
Journal:  Rev Paul Pediatr       Date:  2020-06-05

4.  [Screening for hereditary tyrosinemia and genotype analysis in newborns].

Authors:  Fan Tong; Rulai Yang; Chang Liu; Dingwen Wu; Ting Zhang; Xinwen Huang; Fang Hong; Guling Qian; Xiaolei Huang; Xuelian Zhou; Qiang Shu; Zhengyan Zhao
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-25

5.  A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation.

Authors:  Reza Najafi; Neda Mostofizadeh; Mahin Hashemipour
Journal:  Adv Biomed Res       Date:  2018-01-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.